Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SRNE Sorrento Therapeutics, Inc. daily Stock Chart
SRNE [NASD]
Sorrento Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.25 Insider Own37.74% Shs Outstand175.08M Perf Week-9.93%
Market Cap444.70M Forward P/E- EPS next Y-0.71 Insider Trans0.00% Shs Float104.47M Perf Month-38.94%
Income-279.00M PEG- EPS next Q-0.39 Inst Own19.20% Short Float24.23% Perf Quarter67.11%
Sales25.30M P/S17.58 EPS this Y-8.30% Inst Trans28.13% Short Ratio3.41 Perf Half Y9.96%
Book/sh0.35 P/B7.26 EPS next Y66.30% ROA-46.90% Target Price24.50 Perf Year20.95%
Cash/sh0.20 P/C12.82 EPS next 5Y37.00% ROE-237.00% 52W Range1.39 - 6.50 Perf YTD-24.85%
Dividend- P/FCF- EPS past 5Y-5.70% ROI-34.40% 52W High-60.92% Beta2.72
Dividend %- Quick Ratio0.60 Sales past 5Y115.10% Gross Margin48.00% 52W Low82.73% ATR0.24
Employees382 Current Ratio0.60 Sales Q/Q41.50% Oper. Margin- RSI (14)27.86 Volatility6.36% 7.34%
OptionableYes Debt/Eq5.67 EPS Q/Q-21.80% Profit Margin- Rel Volume0.51 Prev Close2.65
ShortableYes LT Debt/Eq5.11 EarningsMar 06 AMC Payout- Avg Volume7.43M Price2.54
Recom2.00 SMA20-24.01% SMA50-29.80% SMA200-7.97% Volume3,815,673 Change-4.15%
Oct-07-19Initiated JMP Securities Mkt Outperform $21
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Dec-03-13Initiated Aegis Capital Buy $40
Nov-21-13Initiated CRT Capital Buy $11
Feb-21-20 09:15AM  Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference GlobeNewswire
Jan-29-20 07:00AM  Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection GlobeNewswire -6.17%
Jan-27-20 12:21PM  Sorrento Therapeutics rejects near $1 billion offer, shares fall Reuters -9.13%
08:45AM  Sorrento Rejects Takeover Offer Benzinga
07:00AM  Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences GlobeNewswire
07:00AM  Sorrento Board Rejects Latest Acquisition Proposal GlobeNewswire
Jan-10-20 10:59AM  All Bets Are Off for Amarin Stock InvestorPlace +39.59%
10:29AM  Sorrento surges on a near $1 billion takeout offer Reuters
09:03AM  Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR Benzinga
08:30AM  Sorrento shares rise on private equity proposal MarketWatch
07:00AM  Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal GlobeNewswire
Jan-06-20 07:00AM  Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China GlobeNewswire
Dec-16-19 07:00AM  Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors GlobeNewswire
Dec-09-19 07:00AM  Sorrento Announces New Board Member GlobeNewswire +8.24%
Dec-03-19 04:14PM  Sorrento (SRNE) Stock Has More Room to Run, Says Analyst TipRanks +9.06%
Nov-27-19 08:51AM  Implied Volatility Surging for Sorrento (SRNE) Stock Options Zacks
03:32AM  Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps Zacks
Nov-26-19 11:25AM  Analysts See 700% Upside In Sorrento Therapeutics After Unsolicited Takeover Bid Benzinga
Nov-25-19 12:06PM  Sorrento (SRNE) Stock Has Over 700% Upside Potential, Says Analyst TipRanks +94.37%
07:52AM  Sorrento Therapeutics shares soar 25% after it rejects offer from two companies MarketWatch
07:47AM  UPDATE 1-Sorrento Therapeutics rejects all-cash takeout proposal; shares jump Reuters
07:12AM  Sorrento Therapeutics rejects all-cash takeout proposal Reuters
07:00AM  Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal GlobeNewswire
Nov-12-19 07:05AM  Sorrento CEO to Present at Upcoming Investor Conferences GlobeNewswire
Nov-07-19 05:05PM  Sorrentto Therapeutics Inc (SRNE): Are Hedge Funds Right About This Stock? Insider Monkey +7.01%
Nov-06-19 07:37PM  Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences GlobeNewswire
Nov-01-19 10:30AM  Earnings Preview: Sorrento Therapeutics (SRNE) Q3 Earnings Expected to Decline Zacks +7.24%
Oct-15-19 10:36PM  Los Angeles Court Rejects Patrick Soon-Shiongs Attempt to Avoid Sorrento Litigation Allowing Arbitration Case to Move Forward GlobeNewswire
12:28PM  What Kind Of Shareholders Own Sorrento Therapeutics, Inc. (NASDAQ:SRNE)? Simply Wall St.
Oct-09-19 10:35AM  Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering GlobeNewswire
Oct-07-19 02:35PM  Sorrento Therapeutics Announces $25 Million Registered Direct Offering GlobeNewswire -25.52%
Sep-30-19 07:00AM  Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak GlobeNewswire
Sep-23-19 07:00AM  Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering GlobeNewswire
Aug-14-19 08:33AM  Those Who Purchased Sorrento Therapeutics (NASDAQ:SRNE) Shares Three Years Ago Have A 67% Loss To Show For It Simply Wall St.
Aug-01-19 10:33AM  Sorrento Therapeutics (SRNE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -6.32%
Jul-29-19 10:12AM  Moving Average Crossover Alert: Sorrento Therapeutics Zacks
Jul-02-19 12:40PM  Sorrento Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Warrants GlobeNewswire
Jul-01-19 08:46AM  Implied Volatility Surging for Sorrento (SRNE) Stock Options Zacks
Jun-28-19 04:40PM  Why PG&E, Pier 1 Imports, and Sorrento Therapeutics Slumped Today Motley Fool -21.24%
12:18PM  Sorrento Therapeutics News: SRNE Stock Tanks on Equity Offering InvestorPlace
08:37AM  Sorrento Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock and Warrants GlobeNewswire
06:00AM  Sorrento Therapeutics Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Jun-19-19 11:51AM  Sorrento Therapeutics Shares Move On RTX Trial Update Benzinga
07:00AM  Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial GlobeNewswire
07:00AM  Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for Off-The-Shelf Cell Therapy GlobeNewswire
Jun-14-19 07:00AM  Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY) GlobeNewswire
Jun-12-19 07:00AM  Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company GlobeNewswire
Jun-10-19 07:00AM  Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain GlobeNewswire
Jun-05-19 07:00AM  Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration GlobeNewswire
Jun-04-19 07:00AM  Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships GlobeNewswire +5.57%
May-29-19 01:03PM  Why Sorrento Therapeutics Is Getting Crushed Today Motley Fool -10.33%
May-21-19 06:25PM  Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca). GlobeNewswire
May-20-19 08:50AM  Options Traders Expect Huge Moves in Sorrento (SRNE) Stock Zacks
May-03-19 10:32AM  What's in Store for Sorrento (SRNE) This Earnings Season? Zacks
Apr-18-19 08:30AM  Cannabis Bargains After Aphria's News Started Sell-Off-THC Therapeutics, Inc. ACCESSWIRE
Apr-16-19 09:00AM  Sorrento Establishes Business Unit to Address Market Opportunity for Proprietary Water Soluble Cannabidiol (CBD) Formulations GlobeNewswire
Apr-15-19 04:00AM  Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study GlobeNewswire
Apr-10-19 12:42PM  Why Sorrento Therapeutics Is Jumping Today Motley Fool
09:00AM  Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinsons Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration GlobeNewswire
Apr-09-19 12:59PM  Here's Why Sorrento Therapeutics Soared 134% in March Motley Fool
Apr-04-19 03:54PM  Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme American City Business Journals
08:50AM  Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock? Zacks
Apr-03-19 01:50AM  Patrick Soon-Shiong accused of cancer drug catch and kill Financial Times +15.26%
Mar-26-19 08:30AM  Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program GlobeNewswire
Mar-22-19 01:06PM  Sorrento Therapeutics News: Why SRNE Stock Is On The Move InvestorPlace +13.58%
07:00AM  Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management GlobeNewswire
Mar-11-19 07:00AM  Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001 GlobeNewswire
Feb-25-19 07:00AM  Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences GlobeNewswire
Feb-12-19 07:00AM  Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program GlobeNewswire
Feb-08-19 09:06AM  What Kind Of Shareholders Own Sorrento Therapeutics, Inc. (NASDAQ:SRNE)? Simply Wall St.
Jan-31-19 08:20AM  New Research: Key Drivers of Growth for Tapestry, FIS, News Corporation, Ollie's Bargain Outlet, Covanta Holding, and Sorrento Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -5.07%
Jan-22-19 09:30AM  Health Stocks Benefitting the Most from Rally ACCESSWIRE -6.52%
07:00AM  Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019 GlobeNewswire
Jan-14-19 07:00AM  Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1) GlobeNewswire -6.48%
07:00AM  Scilex Announces Addition of ZTlido® to Express Scripts National Formularies GlobeNewswire
Jan-04-19 07:00AM  Dr. Henry Ji to Participate In Financing Expert Panel at East/West CEO Conference GlobeNewswire
Nov-08-18 07:00AM  Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million GlobeNewswire -5.66%
Nov-06-18 08:01AM  Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases GlobeNewswire
Nov-01-18 07:00AM  Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma GlobeNewswire +12.85%
Oct-25-18 08:10AM  Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and PennantPark Floating Rate Capital with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +7.89%
Oct-11-18 05:04PM  Here's Why Sorrento Therapeutics Fell 20.7% in September Motley Fool
Oct-05-18 02:16PM  10 Growth Stocks to Buy With Monster Potential Kiplinger
Oct-01-18 08:00AM  Scilex Announces the Availability of ZTlido GlobeNewswire -6.14%
Sep-27-18 06:09PM  Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018 GlobeNewswire
Sep-19-18 08:00AM  Scilex Announces Pricing and Availability of ZTlido for the Commercial Launch of its First Product in October of 2018 GlobeNewswire
Sep-10-18 04:00AM  Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido Pain Medication GlobeNewswire +11.11%
Sep-07-18 12:24PM  Scilex Presents ZTlido Data on Superior Adhesion over Lidocaine Patch Formulation PR Newswire
Sep-04-18 08:30AM  Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-02-18 01:19PM  Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY) GlobeNewswire
Aug-13-18 09:42AM  Sorrento's Knee Pain Medication Found Safe, Effective Based On Early Data Benzinga
04:00AM  1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations GlobeNewswire
Jul-23-18 08:10AM  Todays Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Sorrento Therapeutics ACCESSWIRE
07:05AM  Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE
Jul-05-18 05:32PM  Why Clean Energy Fuels, Sorrento Therapeutics, and iQiyi Slumped Today Motley Fool -7.75%
04:11PM  Why Sorrento Therapeutics, Inc. Stock Sank Today Motley Fool
Jul-03-18 09:30AM  Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics GlobeNewswire
Jun-26-18 07:15AM  Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE +11.81%
Jun-14-18 04:42PM  Sorrento Therapeutics issues Chairman/CEO corporate update to stockholders GlobeNewswire
10:31AM  Hong Kong market could open cash flood gates for U.S. biotechs Reuters
10:18AM  Hong Kong market could open cash flood gates for U.S. biotechs Reuters
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It also develops CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. The company has a cooperation framework agreement with LifeTech Scientific Corporation for the research and development, production, and commercialization of water-soluble cannabidiol and other water-soluble cannabinoids products; and clinical and manufacturing collaboration with Celularity, Inc. to initiate emergency allogeneic natural killer cell therapy development for coronavirus infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
open in yahoo | open in reuters | open in google